$Recursion Pharmaceuticals (RXRX.US)$ Type of business: Heal...

Type of business: Health care, biotechnology

Business content
We are proceeding with the discovery and development of new pharmaceuticals using a unique platform utilizing artificial intelligence (AI).
・AI drug discovery platform: Large-scale biological data sets are analyzed with AI to identify molecules that cause diseases and new compounds that act on them.
・Drug Discovery Pipeline: We are developing new drug candidates for various diseases based on compounds discovered on our platform.
・Platform license: We may also license our platform to other pharmaceutical companies and proceed with joint research.

Main customers
Recovery Pharmaceuticals's main business model is partnerships and joint research with pharmaceutical companies. Therefore,Major pharmaceutical companiesIt can be said that it is the main customer base.

Future outlook
Along with the advancement of AI, the importance of AI drug discovery is increasing more and more. As a pioneer in this field, Recovery Pharmaceuticals is expected to continue to grow rapidly.
・Pipeline progress: Multiple new drug candidates have advanced to the clinical trial stage, and future pipeline developments will greatly influence performance.
・The evolution of AI technology: Further advances in AI technology will enable more efficient drug discovery and are expected to enhance competitive advantage.
・Partnering with pharmaceutical companies: It is conceivable to expand the business by strengthening partnerships with major pharmaceutical companies and proceeding with joint research.

・AI supercomputers: Recovery Pharmaceuticals uses AI for drug discovery, and NVIDIA GPUs are mounted on supercomputers that are responsible for advanced computational processing capabilities for this purpose. NVIDIA GPUs are known for their high performance in AI processing, and play an important role in accelerating the recovery drug discovery process.

・Investment-related: NVIDIA holds a large amount of shares in Recovery Pharmaceuticals and is making large-scale investments. This investment is aimed at deepening technical synergy between the two companies and strengthening cooperation in the field of AI drug discovery.

・Technical Cooperation: The two companies are collaborating on research and development, and are aiming to develop new treatments by combining NVIDIA's cutting-edge AI technology with recovery biological data and drug discovery platforms.

Drug discovery using AI has the potential to discover new drugs more quickly and efficiently than conventional drug discovery methods.
There are many untreated diseases, and demand for new treatments is high. AI drug discovery is attracting attention as a promising approach to meet this unmet medical need.